Does 81517 require prior authorization?

No, 81517 does not require prior authorization (low confidence). No active coverage policies found for this code.

What is the Medicare reimbursement rate for 81517?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

Verity

`81517`

HCPCS/CPT

Prior Authorization

No Prior Auth Required

No active coverage policies found for this code (low confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

Bill proteomics tests with an appropriate CPT code from the Multianalyte CPT code set, the NOC code 81599, or an applicable PLA code.
Report 1 unit of service (UOS) for the proteomics CPT code on the claim.
Enter the appropriate DEX Z‑Code identifier adjacent to the CPT code in the comment/narrative field for Part B claims: Loop 2400 or SV101‑7 for the 837P electronic claim and Box 19 for paper claims.
Enter the appropriate DEX Z‑Code identifier adjacent to the CPT code in the comment/narrative field for Part A claims: Line SV202‑7 for the 837I electronic claim and Block 80 for the UB‑04 form.

Key Coverage Criteria

A test is considered a proteomics test if it is a multianalyte assay that includes proteins as the major or essential analytes.
A test is considered proteomics if it measures the interactions between analytes, including proteins.
A test is considered proteomics if it requires informatics (e.g., nomograms, rubrics, or algorithms) to produce a result.
A test is considered proteomics if the assay demonstrates clinical validity as a function of the interactions among the analytes measured.
Test is a multianalyte assay that includes proteins as the major or essential analytes.
Test measures the interactions between analytes, including protein–protein or protein–other-analyte interactions.

20 Active Policies

L36807 — MolDX: Molecular Diagnostic Tests (MDT)

J05

L40271 — MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

J05

A59649 — Billing and Coding: MolDX: Proteomics Testing

J05

A60305 — Billing and Coding: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

J05

Have a follow-up question?

Ask Verity about documentation requirements, denial risks, or coverage in your state.

Select and report the appropriate ICD‑10‑CM diagnosis code on the claim for the clinical indication being billed.

When entering the DEX Z‑Code on the SV101‑7 line for Part B claims, do not add additional characters or information on that line.

A59646 — Billing and Coding: MolDX: Proteomics Testing

A60204 — Billing and Coding: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

A60214 — Billing and Coding: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

A60216 — Billing and Coding: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

L35025 — MolDX: Molecular Diagnostic Tests (MDT)

L35160 — MolDX: Molecular Diagnostic Tests (MDT)

L36021 — MolDX: Molecular Diagnostic Tests (MDT)

L36256 — MolDX: Molecular Diagnostic Tests (MDT)

L40186 — MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

L40196 — MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

L40198 — MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

AETNA-CPB-0690 — Noninvasive Tests for Hepatic Fibrosis

AMBETTER-CG-Gastro-Disorders-NonCa-2025.1 — Concert Genetic Testing: Gastroenterologic Disorders (non-cancerous)

ANTHEM-LAB.00019 — LAB.00019 Proprietary Algorithms for Liver Fibrosis

A59636 — Billing and Coding: MolDX: Proteomics Testing

A59641 — Billing and Coding: MolDX: Proteomics Testing

81517